Pilot Study of Delayed, 24 Hour Imaging of Hepatocellular Carcinoma Following the Administration of the Hepatobiliary MRI Contrast Agent Gadolinium Ethoxybenzyl Dimeglumine (Eovist)
Status: Withdrawn prior to enrolment
Phase of Trial: Phase 0
Latest Information Update: 25 Sep 2015
Price : $35 *
At a glance
- Drugs Gadoxetate disodium (Primary)
- Indications Liver cancer
- Focus Pharmacodynamics
- 22 Sep 2015 Status changed from recruiting to withdrawn prior to enrolment, as reported by ClinicalTrials.gov record.
- 09 Dec 2013 Planned end date changed from 1 Nov 2016 to 1 Dec 2016 as reported by ClinicalTrials.gov record.
- 01 Dec 2013 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.